World's Best Scientists 2026 revealed!
Philippe Rougier

Philippe Rougier

D-Index & Metrics

Medicine

D-Index
118
Citations
77869
World Ranking
3974
National Ranking
115

Philippe Rougier publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Philippe Rougier sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 507 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Philippe Rougier D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Philippe Rougier sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 118 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Philippe Rougier is affiliated with the University of Nantes in France, focusing their research primarily within the fields of Medicine and Economics, Econometrics and Finance. Their academic work intersects multiple subfields including Oncology, Surgery, Economics and Econometrics, and Pathology and Forensic Medicine.

Their research addresses various topics, notably:

  • Colorectal Cancer Treatments and Studies
  • Colorectal and Anal Carcinomas
  • Genetic factors in colorectal cancer
  • Economic and Financial Impacts of Cancer
  • Health Systems, Economic Evaluations, Quality of Life

Rougier has contributed to studies published primarily in the venue UNC Libraries, where two of their recorded papers appeared. These publications are:

  • Documenting the Natural History of Patients With Resected Stage II Adenocarcinoma of the Colon After Random Assignment to Adjuvant Treatment With Edrecolomab or Observation: Results From CALGB 9581 (2020, UNC Libraries)
  • Pooled Safety and Efficacy Analysis Examining the Effect of Performance Status on Outcomes in Nine First-Line Treatment Trials Using Individual Data From Patients With Metastatic Colorectal Cancer (2020, UNC Libraries)

Their frequent co-authors include:

  • Richard M. Goldberg
  • Donna Niedzwiecki
  • Monica M. Bertagnolli
  • Robert S. Warren
  • Carolyn C. Compton

Best Publications

  • Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

    Eric Van Cutsem;Claus Henning Köhne;Erika Hitre;Jerzy Zaluski

  • Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

    J Y Douillard;D Cunningham;Arnaud Roth;M Navarro

  • KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer

    Astrid Lièvre;Jean-Baptiste Bachet;Delphine Le Corre;Valérie Boige

  • Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

    Hansjochen Wilke;Kei Muro;Eric Van Cutsem;Sang Cheul Oh

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Bengt Glimelius;Graeme J Poston

  • Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial

    Marc Ychou;Valérie Boige;Jean-Pierre Pignon;Thierry Conroy

  • KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab

    Astrid Lièvre;Jean-Baptiste Bachet;Valérie Boige;Anne Cayre

  • Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

    Wendy De Roock;Bart Claes;David Bernasconi;Jef De Schutter

  • Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

    Eric Van Cutsem;Claus Henning Köhne;István Láng;Gunnar Folprecht

  • Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.

    H Bartelink;F Roelofsen;F Eschwege;P Rougier

  • Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer.

    P Piedbois;P Rougier;M Buyse

  • Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983) : long-term results of a randomised, controlled, phase 3 trial

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Graeme J Poston

  • Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

    Eric Van Cutsem;Chris Twelves;Jim Cassidy;David Allman

  • Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer

    Philippe Rougier;Eric Van Cutsem;Emilio Bajetta;Norbert Niederle

  • A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.

    P. Rougier;A. Adenis;M. Ducreux;M. de Forni

  • Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer A Meta-analysis

    Gastric (Global Advanced);Xavier Paoletti;Koji Oba

  • Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment and RAS Mutations in Colorectal Cancer

    Eric Van Cutsem;Heinz Josef Lenz;Claus Henning Köhne;Volker Heinemann

  • Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study

    B. Chauffert;F. Mornex;Franck Bonnetain;P. Rougier

  • Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases.

    Mehdi Karoui;Christophe Penna;Mohamed Amin-Hashem;Emmanuel Mitry

  • Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983)

    Bernard Nordlinger;Halfdan Sorbye;Bengt Glimelius;Graeme J Poston

Frequent Co-Authors

Michel Ducreux
Michel Ducreux Institut Gustave Roussy
Olivier Bouché
Olivier Bouché CHU de Reims
Julien Taieb
Julien Taieb Université Paris Cité
Marc Ychou
Marc Ychou University of Montpellier
Valérie Boige
Valérie Boige Institut Gustave Roussy
Dominique Elias
Dominique Elias Institut Gustave Roussy
Pierre Laurent-Puig
Pierre Laurent-Puig Université Paris Cité
René Adam
René Adam University of Paris-Saclay
Jean-Luc Raoul
Jean-Luc Raoul Institut de Cancérologie de l'Ouest (ICO)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in healthcare but not sure if a traditional MD is the right fit? There are many alternative online pathways for future healthcare professionals. Nursing is a fast-growing field with plenty of flexible study options. For those seeking advanced education, online nursing doctoral programs provide opportunities for leadership, research, and teaching roles—all from the convenience of home.

For registered nurses aiming to advance their credentials, the cheapest online BSN programs offer affordable pathways to a Bachelor of Science in Nursing, often on a flexible schedule. Those with a non-nursing background can also consider direct entry nurse practitioner programs for non-nurses online, which offer a fast track to becoming a nurse practitioner, even without prior nursing experience.

Wondering where to begin your journey? Some institutions are known for being more accessible. Explore the easiest RN program options to help kick-start your nursing education and get hands-on experience quickly. Exploring these diverse online degrees and career pathways can open doors to meaningful roles across the healthcare sector.

Best Scientists Citing Philippe Rougier

Trending Scientists

Recently Published Articles